NCT02160015View on ClinicalTrials.gov

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 20, 2014

Primary Completion Date

March 27, 2017

Study Completion Date

August 13, 2026

Conditions
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Electrocardiogram

Undergo ECG

DRUG

Ibrutinib

Given PO

DRUG

Lenalidomide

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Rituximab

Given IV

Trial Locations (2)

20007

MedStar Georgetown University Hospital, Washington D.C.

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH